Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
CHMP says no to Laquinimod
After Failing Phase III, Active Biotech is back to square one - Labiotech.eu
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
Prostate Cancer Therapeutics Market Competitive Landscape
Active Biotech's partner Teva starts laquinimod clinical trial
3 Reasons to Buy Teva Right Now - TheStreet
Teva Pharmaceuticals - Wikipedia
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, ppt download
Teva recalls US-made drugs following contamination fears - The Boston Globe
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
The top 10 leading biotech companies | biotechworldwide.net
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
PharmaShots | Incisive News in 3 Shots
Active Biotech Pivots Away from MS and Huntington's Disease, Goes in New Direction | BioSpace
Active Biotech Regains Rights Over Laquinimod from Teva Pharmaceutical
Tweets with replies by Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails
Teva and Active Signs Agreement to Study By CIOReview Team
Teva and Active Biotech Announce Concerto Trial of Laquinimod did not Meet Primary Endpoint | Pharmasources.com
Active Biotech provides update on laquinimod in Huntington's disease - Huntington's Disease News
Active Biotech - News, Articles etc. - European Pharmaceutical Review
Teva returns laquinimod global rights to Active Biotech
